期刊文献+

BRCA1、Ki67在不同分子分型乳腺癌中的表达及临床病理意义 被引量:12

Clinical Pathological Significance of BRCA1 and Ki67 Expression in Different Molecular Classification of Breast Cancer
下载PDF
导出
摘要 目的探讨BRCA1、Ki67在不同分子分型乳腺癌进展中的作用、临床病理意义。方法应用荧光原位杂交技术(FISH),对免疫组化方法检测Her2为2+以上(包含2+)的肿瘤蜡块做进一步检测,FISH检测出阳性表达的肿瘤蜡块定义为Her2最终阳性表达,并依据《2013版中国抗癌协会乳腺癌诊治指南与规范的标准》对乳腺浸润性导管癌进行分子分型,依据分子分型将乳腺癌分为五类Luminal A型,Luminal B like型,Luminal B样型,Her2过表达型和基底细胞样型,各分型分别选取20例,总共100例乳腺浸润性导管癌病例。采用免疫组化二步法对入选病例的肿瘤组织进行BRCA1及Ki67蛋白的检测。结果 BRCA1蛋白阳性表达率在Luminal A型组,Luminal B like型组,Luminal B样型组,Her2过表达型组,基底细胞样型组中差异具有明显显著性(P<0.05);BRCA1蛋白表达与年龄、肿瘤大小、肿瘤距乳头距离、组织学分级、腋窝淋巴结转移情况、ER/PR状态、Her2状态均无关(P均>0.1);Ki67高指数表达率在Luminal A型组,Luminal B like型组,Luminal B样型组,Her2过表达型组,基底细胞样型组中差异具有明显显著性(P<0.05);年龄组≤59岁的Ki67高指数表达率较年龄组≥60岁的增高,差异有统计学意义(P<0.1);ER/PR阴性组和Her2阳性组的Ki67高指数表达率较ER/PR阳性组和Her2阴性组增高,差异具有统计学意义(P<0.1);Ki67表达与肿瘤大小、肿瘤距乳头距离、组织学分级、腋窝淋巴结转移等临床病理指标无相关性(P均>0.1);BRCA1与Ki67在各亚型乳腺癌中的表达呈负相关性(P<0.05)。结论联合检测BRCA1和Ki67对不同分子分型乳腺癌有一定的预测预后价值。 Objective To investigate the effect of BRCA1 and Ki67 in different molecular subtypes of breast cancer,and its clinical pathological significance.Methods Testing the tumor wax block by using FISH method which were Her2 2 + or 3 +detected by immunohistochemical method.FISH method showed the positive expression of tumor wax block was defined as Her2 positive expression,eventually.Classificating breast invasive ductal carcinoma in molecular classification according to the 2013 edition of the Chinese anti-cancer association guidelines and normative standard of diagnosis and treatment of breast cancer,and the breast cancer can be divided into 5 subtypes in molecular classification: Luminal A subtype group,Luminal B like subtype group,Luminal B subtype group,Her2 over-expression subtype group,basal-like subtype group.Select 15 cases from each subtype,total of 75 cases of breast invasive ductal carcinoma.Detected BRCA1 and Ki67 protein in each tumor tissues by immunohistochemical SP method and analyzed its relationship with the clinical pathological indicators.Results Positive expression rate of BRCA1 protein had obviously significant difference in the Luminal A subtype group,Luminal B like subtype group,Luminal B subtype group,Her2 over-expression subtype group and basal-like subtype group(P〈0.05); There were no significant differences with the expression of BRCA1 protein and age,tumor size,tumor distance from the nipple,histological grade and axillary lymph node metastasis,ER/PR status as well as Her2 status(P〉0.1); High index expression rate of Ki67 had obviously significant difference in the Luminal A subtype group,Luminal B like subtype group,Luminal B subtype group,Her2 over-expression subtype group and basallike subtype group(P〈0.05); High index expression rate of Ki67 in the ≤59 group was more than ≥60 group,the difference was statistically significant(P〈0.1); High index expression rate of Ki67 in ER/PR negative group and Her2 positive group was more than that in ER/PR positive group and her2-negative group,the difference had statistical significance(P〈0.1); There were no significant differences in the expression of Ki67 protein and tumor size,tumor distance from the nipple,histological grade as well as axillary lymph node metastasis(P〉0.1); The expression of BRCA1 and Ki67 in different subtypes of breast cancer showed a negative correlation(P〈0.05).Conclusion Joint detection of BRCA1 and Ki67 in different molecular classification of breast cancer might play an important role in predicting clinical outcomes.
出处 《实用癌症杂志》 2016年第10期1582-1586,共5页 The Practical Journal of Cancer
关键词 乳腺肿瘤 不同分子分型乳腺浸润性导管癌 BRCA1 KI67 免疫组织化学 FISH检测 Breast neoplasms Different molecular classification of breast invasive ductal carcinoma BRCA1 Ki67 Immunohistochemistry FISH detection
  • 相关文献

参考文献12

  • 1王芳,杨红鹰.基底细胞样乳腺癌的研究进展[J].诊断病理学杂志,2011,18(5):384-386. 被引量:4
  • 2Viale G, Giobbie-Hurder A, Regan M, et al. Prognostic and predictivevalue of centrally reviewed Ki-67 labeling index in postmenopausalwomen with endocrine-responsive breast cancer: resultsfrom breast international group trial 1-98 comparing adjuvanttamoxifen with letrozole [ J ]. J Clin On- col, 2008,26 ( 34 ) : 69 -75.
  • 3Yip CH, Taib NA, Choo WY, et al. Clinical and pathologic differences between BRCAI-, BRCA2-, and Non-BRCA-as- sociated breast cancers in a multiracial developing country [J]. World J Surg,2009,33 (10) :2077-2081.
  • 4中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2013版)[J].中国癌症杂志,2013,23(8):637-693. 被引量:493
  • 5Dent R, Trudean M, Pritchard KI, et al. Triple-negative br- east cancer: Clinical features and pattern a of recurrence [ J ].Olin Cancer Res,2007,13 ( 15 Pt 1 ) :4429-4434.
  • 6杨利利,艾秀清,贺春钰,朱相露,木妮热·木沙江.621例乳腺浸润性导管癌患者分子分型与临床病理学特征的关系[J].实用肿瘤学杂志,2015,29(1):34-38. 被引量:7
  • 7Livasy C A, Karaca G, Nanda R, et al. Phenotypic evalua- tion of the basal-like subtype of invasive breast carcinoma [ J ]. Mod Patho1,2006,19 (2) :264-271.
  • 8孙燕翔,黄天祖,杨乐,黄建平.组蛋白酶D和c-erbB-2在乳腺癌中的表达及其与预后的关系[J].肿瘤研究与临床,2011,23(2):103-105. 被引量:3
  • 9Taneja P, Maglic D, Kai F, et al. Classical and novel prog- nostic markers for breast cancer and their clinical signifi- cance[ J]. Clin Med Insights Oncol,2010,4 : 15-34.
  • 10Silva Soares EW, de Lima Santos SC, Bueno AG, et al. Con- comitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer [J ]. Cancer Gene Cytogenet,2010,199 ( 1 ) :24-30.

二级参考文献60

  • 1夏长华,孙燕翔.乳腺癌组织蛋白酶D的表达及DNA含量和雌激素受体的测定[J].现代诊断与治疗,1996,7(5):299-300. 被引量:2
  • 2孙燕翔,夏长华.组蛋白酶D和乳腺癌预后[J].现代诊断与治疗,1997,8(1):35-36. 被引量:2
  • 3陈莉颖,陈红风,付娜,叶媚娜.218例不同分子亚型浸润性乳腺癌患者的临床特征[J].现代肿瘤医学,2007,15(8):1094-1097. 被引量:12
  • 4Aoyama K, Kamio T, Nishikawa T, et al. A comparison of HERZ/neu gene coamplification and its protein overexpression between primary breast cancer and metastatic lymph nodes. Jpn J Clin Oncol, 2010, 40: 613-619.
  • 5Hansel DE, Swain E, Dreicer R, et al. HER-2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplificatian in a subset of cases. Am J Clin Pathol, 2008, 130: 274-281.
  • 6Clavarezza M, Venturini M. Adjuvant chemotherapy for the treatment of HER-2 positive early breast cancer. Oncology, 2009, 77: 14-17.
  • 7Chang J, Clark GM, Aured DC, et al. Survival of patients with metastatic breast carcinoma:importance of prognostic markers of the primary tumor. Cancer, 2003, 79: 545-553.
  • 8Beenken SW, Grizzle WE, Crowe DR, et al. Molercular biomarkers for breast cancer prognosis:coexpression of c-erbB-2 and p53. Ann Surg, 2001, 233: 630-638.
  • 9Gaci Z, Bouin-Pineau MH, Gaci M, et al. Prognostic impact of cathepsin D and c-cerbB-2 oncoprotein in a subgroup of node-negative breast cancer patient with low histological grade tumors. Int J Oncol, 2001, 18: 793-800.
  • 10Sorlie T, Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci USA, 2001, 98 (19) : 10869 - 10874.

共引文献507

同被引文献93

引证文献12

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部